Multiple Stress Fractures in a Young Cancer Patient on Long-Term Zoledronic Acid: A Case Report and Review of Literature
Authors:
Open Access
- 23 September 2024
- journal article
- case report
- Published by Springer Nature in Cureus
- Vol. 16 (9) , e69999
Abstract
Bisphosphonates are commonly used in the treatment of osteoporosis and metastatic cancer patients with bone complications. Stress fractures are a well-known complication of long-term bisphosphonate treatment. Cancer patients receive much higher cumulative doses of bisphosphonates than osteoporotic patients and are subject to a higher risk of bisphosphonate-associated stress fractures. While there is an increasing number of reports of bisphosphonate-associated atypical femoral fractures (AFFs) and non-femoral stress fractures in osteoporotic patients, reports of such fractures in cancer patients are much rarer, especially non-femoral stress fractures. We present the first case report of an atypical subtrochanteric femur fracture following a sequential bilateral Jones fracture in a young non-osteoporotic patient with metastatic breast cancer after 12 years of zoledronic therapy. She sustained a left Jones fracture after seven years of zoledronic acid therapy and a right Jones fracture after 11 years of zoledronic acid therapy. She continued receiving regular zoledronic acid after these stress fractures and sustained a right subtrochanteric fracture after 12 years of zoledronic acid therapy. Both Jones fractures were treated conservatively, while the right subtrochanteric fracture was surgically fixed. Zoledronic acid was stopped after she sustained the AFF. This study highlights the need to look out for stress fractures beyond the commonly reported AFFs and atypical ulnar fractures when administering zoledronic acid to cancer patients.Keywords
This publication has 20 references indexed in Scilit:
- Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agentsJournal of Bone Oncology, 2023
- Intractable Fractures of the Bilateral Proximal Ulnae After 8 Years of Zoledronate Treatment for Breast Cancer Bone MetastasisThe Journal of Hand Surgery, 2022
- Dosing of zoledronic acid with its anti-tumor effects in breast cancerJournal of Bone Oncology, 2015
- Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2013
- Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapyBone, 2012
- Bilateral ulna fractures associated with bisphosphonate therapyOsteoporosis International, 2012
- Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control studyOsteoporosis International, 2008
- An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?Injury, 2008
- Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapyJournal of Bone and Mineral Metabolism, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007